Jazz Pharmaceuticals (JAZZ) Proxy filing summary

Executive summary

• The proxy statement outlines proposals for the 2026 Annual General Meeting, including director elections, auditor ratification, executive compensation, and share issuance authorities.

• The company reported $4.3B in total revenues and $1.4B net cash from operations in 2025, serving ~100 countries with 2,800 employees and 9 marketed medicines.

• Key 2025 achievements include record financial performance, multiple regulatory approvals, and significant pipeline progress, notably in rare diseases and oncology.

• Forward-looking statements emphasize growth through commercial launches, R&D, and strategic capital deployment.

Voting matters and shareholder proposals

• Shareholders will vote on electing three directors, ratifying KPMG as auditor, approving executive compensation, granting share issuance authorities, and potential adjournment.

• Board recommends voting FOR all proposals, including renewal of share allotment and pre-emption opt-out authorities under Irish law.

• Proposals support flexibility for strategic transactions and capital raising, aligning with growth strategy.

Board of directors and corporate governance

• Board consists of 13 members with diverse skills in biopharma, finance, M&A, and global operations; 11 are independent.

• Recent board refreshment added four directors since 2024, balancing tenure and expertise.

• Annual self-evaluation and periodic third-party assessments ensure board effectiveness.

• Board committees include Audit, Compensation, Nominating, and Science & Medicine, all with independent members.

• Share ownership guidelines and anti-hedging/pledging policies are in place for directors and executives.